Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
Come on Sareum .. how much more validation does TYK need .. take us over the finish line already !
https://twitter.com/sparksinsurrey/status/1373903366707945473?s=20
Thanks Basser - however im still unclear from reading the RNS again whether work started in Oct or they waited until formal confirmation in Dec .. it will be a bit ludicrous if they started the work in Dec, knowing the grant was in the bag .. but from past experience of the snail pace they work at wouldn't surprise me ..
i'll email Sareum to see if they can clarify
https://www.marketwatch.com/story/merck-to-discontinue-development-of-covid-19-vaccines-focus-on-two-investigational-therapies-2021-01-25
Do the more knowledgeable have any idea whether MK-7110 and MK-4482 (molnupiravir) are related to TYK / JAK class of drugs??
https://twitter.com/triparnasen/status/1347294490122461189?s=20
Now that she's had her vaccine time to move our 737 along ..
Loving this sentence in the RNS ..
"The Board believes that the patent will enhance the value of its
TYK2/JAK1 inhibitor programmes and the Company's negotiating position as it
continues to engage in discussions with potential licence partners."
arumel @ yahoo dot com
Pls send a template to me: arumel**********
Thanks
Guys, anyone noticed that UKRI hass recently given some funding to GSK and The University of Nottingham for some JAK/TYK work .. abstract of the funding:
"Many biological processes are predicated on the binding of endogenous ligands and other protein-protein interactions that form part of a signaling cascade. Understanding the core components and interactions of these signaling cascades is still elusive for a number of cellular mechanisms with limited tools available to aid deconvolution. This study seeks to utilise the NanoBRET Tracer and protein-protein interaction (PPI) technology to target and better understand elements of a known signaling pathway (IL23R/JAK family/STAT) in a cellular context."
Link:
https://gtr.ukri.org/projects?ref=studentship-2106690#/tabOverview
Its from page34 of the new FORM 10-Q
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=115421026&type=PDF&symbol=SRRA&companyName=Sierra+Oncology+Inc.&formType=10-Q&dateFiled=2020-11-05&CK=1290149
"While we have currently suspended development of SRA737, we are exploring options for potential future development of this product candidate, if any.
However, there can be no assurance that we will successfully obtain development support or the funding necessary to advance SRA737 on commercially
reasonable terms, or at all. If we are unable to obtain such support or funding, we may need to permanently cease development of SRA737"
Does this mean SAR getting it back??